Form 4: SeaStar Medical Director Reports RSU Vesting and New Equity Grant

SeaStar Medical Holding Corp. Director Bernadette N. Vincent reported the vesting of 2,667 restricted stock units and the grant of an additional 4,000 restricted stock units, increasing her total beneficial ownership to 12,000 shares.

Summary

• Director Bernadette N. Vincent reported changes in her beneficial ownership of SeaStar Medical Holding Corp. common stock.
• On June 4, 2025, 2,667 restricted stock units (RSUs) vested and converted into shares of ICU common stock. These RSUs were part of an 8,000 RSU grant awarded on November 13, 2024, with vesting scheduled in three approximately equal annual installments from June 4, 2024.
• Following this vesting, beneficial ownership was reported as 8,000 shares, which includes 5,333 shares underlying unvested RSUs previously reported in Table II and now moved to Table I.
• On July 10, 2025, an additional 4,000 RSU award was granted. These new RSUs are scheduled to vest in full on July 3, 2026.
• Total beneficial ownership after these transactions is 12,000 shares of common stock.

Sentiment

Score: 6

Explanation: Slightly positive due to the director receiving new equity grants and vesting of existing ones, indicating continued alignment of interests and standard compensation practices. No negative transactions were reported.

Positives

• Director Bernadette N. Vincent received a new grant of 4,000 restricted stock units, aligning her interests with shareholders.
• 2,667 restricted stock units vested, converting into common stock, indicating progress on prior compensation agreements.
• Increased total beneficial ownership by a director, which can be seen as a positive signal of commitment.

Future Outlook

The 4,000 RSU award is scheduled to vest in full on July 3, 2026. The remaining 5,333 RSUs from the November 2024 grant are expected to vest in two approximately equal annual installments on June 4, 2026, and June 4, 2027.

Industry Context

This is a routine insider transaction report, common across all industries for publicly traded companies, reflecting standard executive compensation practices involving equity awards. It does not provide specific industry-related insights.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting equity compensation.
• The grant of RSUs and their vesting are common practices for compensating directors in publicly traded companies across various sectors, including biotech/medical device companies like SeaStar Medical.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transactions.

Related Party Transactions

• The RSU grants are related party transactions (company to director) but are standard compensation and not unusual related party dealings.

Stakeholder Impact

• Shareholders: Increased transparency regarding director equity ownership and compensation. The grant of RSUs aligns the director's interests with long-term shareholder value.

Next Steps

• Remaining 5,333 RSUs from the November 2024 grant are expected to vest in two approximately equal annual installments on June 4, 2026, and June 4, 2027.
• The newly granted 4,000 RSUs are expected to vest in full on July 3, 2026.

Key Dates

Keywords

SeaStar Medical Holding Corp, ICU, Form 4, Insider Trading, Restricted Stock Units, RSU, Beneficial Ownership, Director Compensation, Equity Grant, Stock Vesting